Get the Report Now
Everyone is thinking about biosimilars as the market anticipates a wave of Humira competitors. This report breaks down these innovative treatments, the current state of the market, and the potential for the autoimmune category.
With so many entrants in 2023 and 2024, the autoimmune category will see increased competition and significant savings.
Learn the major considerations for biosimilar adoption. There are many complex factors beyond cost to weigh when evaluating biosimilars – and here’s your guide to navigate this dynamic landscape.
- What biosimilars are and their savings potential
- Important considerations for biosimilar use
- Expected launches and pipeline highlights
- How our lowest net cost strategy maximizes savings for clients and members